- Ertugliflozin reduces total heart failure events by 34% and serious events by 38% in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
- The study involved 8,238 participants with a mean follow-up of 3.5 years.
- Adjudicated hospitalizations for heart failure and broader investigator-reported heart failure adverse events were evaluated.
- Ertugliflozin significantly reduced the risk of heart failure adverse events by 31% and serious adverse events by 34%.
- Peripheral edema adverse events were also reduced by 42%.
- No significant reduction was observed in orthopnea/dyspnea. The results were constrained by the retrospective design of the analyses.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
